X4 Pharmaceuticals Inc (NASDAQ: XFOR) on Monday, plunged -8.28% from the previous trading day, before settling in for the closing price of $0.40. Within the past 52 weeks, XFOR’s price has moved between $0.26 and $1.60.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -20.00% over the past five years. The company achieved an average annual earnings per share of 77.49%. With a float of $117.17 million, this company’s outstanding shares have now reached $167.43 million.
Let’s look at the performance matrix of the company that is accounted for 93 employees. In terms of profitability, gross margin is 85.2%, operating margin of -618.81%, and the pretax margin is -398.61%.
X4 Pharmaceuticals Inc (XFOR) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of X4 Pharmaceuticals Inc is 31.29%, while institutional ownership is 35.58%. The most recent insider transaction that took place on Nov 15 ’24, was worth 13,078. Before that another transaction happened on Oct 15 ’24, when Company’s President and CEO sold 31,897 for $0.56, making the entire transaction worth $17,926. This insider now owns 1,025,816 shares in total.
X4 Pharmaceuticals Inc (XFOR) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 77.49% per share during the next fiscal year.
X4 Pharmaceuticals Inc (NASDAQ: XFOR) Trading Performance Indicators
X4 Pharmaceuticals Inc (XFOR) is currently performing well based on its current performance indicators. A quick ratio of 4.80 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 55.47.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.09, a number that is poised to hit -0.16 in the next quarter and is forecasted to reach -0.49 in one year’s time.
Technical Analysis of X4 Pharmaceuticals Inc (XFOR)
X4 Pharmaceuticals Inc (NASDAQ: XFOR) saw its 5-day average volume 15.85 million, a positive change from its year-to-date volume of 2.36 million. As of the previous 9 days, the stock’s Stochastic %D was 31.84%. Additionally, its Average True Range was 0.08.
During the past 100 days, X4 Pharmaceuticals Inc’s (XFOR) raw stochastic average was set at 17.09%, which indicates a significant decrease from 26.00% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 369.75% in the past 14 days, which was higher than the 156.03% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.5745, while its 200-day Moving Average is $0.8485. Nevertheless, the first resistance level for the watch stands at $0.3868 in the near term. At $0.4036, the stock is likely to face the second major resistance level. The third major resistance level sits at $0.4172. If the price goes on to break the first support level at $0.3564, it is likely to go to the next support level at $0.3428. The third support level lies at $0.3260 if the price breaches the second support level.
X4 Pharmaceuticals Inc (NASDAQ: XFOR) Key Stats
Market capitalization of the company is 62.12 million based on 170,546K outstanding shares. Right now, sales total 0 K and income totals -101,170 K. The company made 560 K in profit during its latest quarter, and 90,830 K in sales during its previous quarter.
